GlucoBeam: A portable device for pain-free glucose self-monitoring in diabetic patients

Projektinformationen

GlucoBeam

ID Finanzhilfevereinbarung: 738973

DOI 10.3030/738973

Abgeschlossenes Projekt

EK-Unterschriftsdatum 26 Februar 2017

Startdatum 1 März 2017

Enddatum 30 September 2021

Finanziert unter

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Gesamtkosten € 5 219 875,00

EU-Beitrag € 2 348 943,75

Koordiniert durch

RSP SYSTEMS A/S
Denmark

Ziel

Diabetes mellitus (DM) is one of the largest health challenges currently faced by modern society, affecting over 400 million people in the world. DM cannot be cured, but via well-controlled therapy, a high quality of life with diabetes can be obtained, with a minimum of short- and long-term complications. The key to a successful diabetes therapy is a well-controlled blood glucose level, which is obtained by carefully balancing insulin intake, diet, and exercise and with Self-Monitoring of Blood Glucose (SMBG) as a cornerstone. Conventional SMBG is an invasive test requiring the patient to prick his/her finger with a lancet to extract a blood droplet onto a disposable strip for electrochemical analysis of the glucose concentration. Repeating this uncomfortable and painful task 4-8 times per day leads to severe loss in life quality, often resulting in poor compliance
leading to costly complications.

RSP’s proprietary non-invasive SMBG technology relies on the capabilities of Raman spectroscopy for directly detecting
individual substances, refined by a unique critical depth optical scanning to collect glucose signals from the right tissue depth
range, thus avoiding sources of errors during the measurement. Our GlucoBeam device will enable DM patients to test their
glucose levels in around 30s and as often as desired – at no added cost or pain – thereby empowering them to better
manage their treatment and minimizing the risk for acute complications.

GlucoBeam’s successful commercialization will position RSP to secure an aggregated turnover of approx. €253 million over
the 5 years post-project period. Furthermore, it has the potential to reach double digit billion savings for EU’s healthcare
systems and will ultimately lead to significantly improved life quality for the large population of diabetic patients. Moreover,
GlucoBeam’s commercialization will allow RSP to set a market foothold in order to leverage its medium term innovation
strategy.

Wissenschaftliches Gebiet

• natural sciences › computer and information sciences › data science
• medical and health sciences › clinical medicine › endocrinology › diabetes
• medical and health sciences › health sciences › nutrition
• natural sciences › physical sciences › optics › spectroscopy

Schlüsselbegriffe

• Diabetes mellitus
• Self-Monitoring of Blood Glucose
• Non-invasive testing
• Raman Spectroscopy

Programm/Programme

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme
• H2020-EU.3.1.4. - Active ageing and self-management of health
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
• H2020-EU.3.1.6. - Health care provision and integrated care

Thema/Themen

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well

Aufforderung zur Vorschlagseinreichung

H2020-SMEInst-2016-2017

Andere Projekte für diesen Aufruf anzeigen

Unterauftrag

H2020-SMEINST-2-2016-2017

Finanzierungsplan

SME-2 - SME instrument phase 2

Koordinator

RSP SYSTEMS A/S

• Netto-EU-Beitrag: € 2 348 943,75
• Adresse: SIVLANDAENGET 27 C HJALLESE ; 5260 Odense S ; Dänemark
• KMU Die Organisation definierte sich zum Zeitpunkt der Unterzeichnung der Finanzhilfevereinbarung selbst als KMU (Kleine und mittlere Unternehmen). Ja:
  Region
  Danmark › Syddanmark › Fyn
• Region: Danmark › Syddanmark › Fyn
• Aktivitätstyp: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Gesamtkosten: € 5 219 875,00